Literature DB >> 18680722

VEGF receptor protein-tyrosine kinases: structure and regulation.

Robert Roskoski1.   

Abstract

The human VEGF family consists of VEGF (VEGF-A), VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PlGF). The VEGF family of receptors consists of three protein-tyrosine kinases (VEGFR1, VEGFR2, and VEGFR3) and two non-protein kinase co-receptors (neuropilin-1 and neuropilin-2). These components participate in new blood vessel formation from angioblasts (vasculogenesis) and new blood vessel formation from pre-existing vasculature (angiogenesis). Interaction between VEGFR1 and VEGFR2 or VEGFR2 and VEGFR3 alters receptor tyrosine phosphorylation.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18680722     DOI： 10.1016/j.bbrc.2008.07.121

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  90 in total

1.  VEGF and VEGFR1 levels in different regions of the normal and preeclampsia placentae.

Authors:  Akriti S Sahay; Anjali T Jadhav; Deepali P Sundrani; Girija N Wagh; Savita S Mehendale; Preeti Chavan-Gautam; Sadhana R Joshi
Journal:  Mol Cell Biochem       Date:  2017-08-02       Impact factor: 3.396

2.  Effect of semax and its C-terminal fragment Pro-Gly-Pro on the expression of VEGF family genes and their receptors in experimental focal ischemia of the rat brain.

Authors:  Ekaterina V Medvedeva; Veronika G Dmitrieva; Oksana V Povarova; Svetlana A Limborska; Veronika I Skvortsova; Nikolay F Myasoedov; Lyudmila V Dergunova
Journal:  J Mol Neurosci       Date:  2012-07-08       Impact factor: 3.444

3.  Quantification and cell-to-cell variation of vascular endothelial growth factor receptors.

Authors:  P I Imoukhuede; Aleksander S Popel
Journal:  Exp Cell Res       Date:  2010-12-23       Impact factor: 3.905

4.  Cloning and expression of soluble vascular endothelial growth factors receptor-1 (sFlt-1) fragments in CHO-K1.

Authors:  Poopak Farnia; Mojgan Bandehpour; Jalaledin Ghanavi; Bahram Kazemi
Journal:  Int J Clin Exp Med       Date:  2013-09-25

5.  A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion.

Authors:  Xin Shi; Yongqiang Deng; Huajing Wang; Guanghui Ji; Wenlong Tan; Tao Jiang; Xiaofeng Li; Hui Zhao; Tian Xia; Yanchun Meng; Chao Wang; Xiaojie Yu; Yang Yang; Bohua Li; E-De Qin; Jianxin Dai; Cheng-Feng Qin; Yajun Guo
Journal:  MAbs       Date:  2016-02-23       Impact factor: 5.857

6.  Increased production of soluble vascular endothelial growth factors receptor-1 in CHO-cell line by using new combination of chitosan-protein lipid nanoparticles.

Authors:  Poopak Farnia; Jalaledin Ghanavi; Afshin Bahrami; Mojgan Bandehpour; Bahram Kazemi; Ali Akbar Velayati
Journal:  Int J Clin Exp Med       Date:  2015-01-15

Review 7.  The alpha,alpha-difluorinated phosphonate L-pSer-analogue: an accessible chemical tool for studying kinase-dependent signal transduction.

Authors:  Kaushik Panigrahi; MariJean Eggen; Jun-Ho Maeng; Quanrong Shen; David B Berkowitz
Journal:  Chem Biol       Date:  2009-09-25

8.  Anti-angiogenic effects of differentiation-inducing factor-1 involving VEGFR-2 expression inhibition independent of the Wnt/β-catenin signaling pathway.

Authors:  Tatsuya Yoshihara; Fumi Takahashi-Yanaga; Fumie Shiraishi; Sachio Morimoto; Yutaka Watanabe; Masato Hirata; Sumio Hoka; Toshiyuki Sasaguri
Journal:  Mol Cancer       Date:  2010-09-16       Impact factor: 27.401

9.  Alternate processing of Flt1 transcripts is directed by conserved cis-elements within an intronic region of FLT1 that reciprocally regulates splicing and polyadenylation.

Authors:  Christie P Thomas; Nandita S Raikwar; Elizabeth A Kelley; Kang Z Liu
Journal:  Nucleic Acids Res       Date:  2010-04-12       Impact factor: 16.971

10.  Myocardial hypertrophy overrides the angiogenic response to hypoxia.

Authors:  Yeong-Hoon Choi; Douglas B Cowan; Meena Nathan; Dimitrios Poutias; Christof Stamm; Pedro J del Nido; Francis X McGowan
Journal:  PLoS One       Date:  2008-12-29       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.